What are you looking for?
This episode of The Ophthalmic Project explores the 100-year legacy of ZEISS in the United States, tracing its origins from a small optics workshop in 1846 to a global leader...
This episode of The Ophthalmic Project explores the 100-year legacy of ZEISS in the United States, tracing its origins from a small optics workshop in 1846 to a global leader...
In this episode of The Ophthalmic Project, host Mark Dlugoss and guest Sam Barone, MD, discuss Nanoscope Therapeutics’ new optogenetic therapy to help restore vision in patients with retinal diseases...
In the latest episode of The Ophthalmic Project, host Mark Dlugoss speaks with Michael O’Rourke, CEO of Re-Vana Therapeutics, about the company’s 2 biodegradable, photocrosslinked ocular drug delivery platforms: EyeLief... ...
In the latest episode of The Ophthalmic Project, Mark Dlugoss hosts Jean-Pierre Hubschman, MD, CEO of Horizon Surgical Systems, and Uday Devgan, MD, who talk about Horizon Surgical System’s robotic... ...
The latest episode of The Ophthalmic Project, pairs host Mark Dlugoss with Rob Sambursky, MD, Chief Executive Officer of DefEYE, where they discuss the company’s products Biovance and Biovance 3L... ...
In the latest episode of The Ophthalmic Project, Mark Dlugoss hosts Nicole Bajic, MD, a comprehensive ophthalmologist and assistant professor at the Cleveland Clinic’s Cole Eye Institute. Dr. Bajic says... ...
In the latest episode of The Ophthalmic Project, Mark Dlugoss speaks with Edward Holland, MD, and Stephen Lane, MD, discuss the goals of The Holland Foundation for Sight Restoration. Through...
In a new episode of The Ophthalmic Project, Mark Dlugoss speaks with Rich Small, CEO of Neurotech, to discuss their newly FDA-approved treatment for macular telangiectasia (MacTel). Mark Dlugoss: In...